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Case Report
JUVENILE MYELOMONOCYTIC LEUKAEMIA
Emad uddin Siddiqui1, Shaheena Hanif2
Summary
Juvenile Myelomonocytic Leukemia (JMML) is a rare hematopoietic malignancy of early
childhood. Infection remains the principal cause of death in patients with myelodysplastic
syndrome (MDS). Sixty percent of patients are anemic and 26 percent have petechiae and/or
purpura (thrombocytopenia). Bone Marrow Transplant (BMT) is the best available treatment
option. We describe the management of an eight months old male child who presented with
complaints of fever, cough and pallor since six months. Despite medication his fever did not
subside. He developed meningitis and intracranial bleed and expired on 11th day of
hospitalization.
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INTRODUCTION
Juvenile myelomonocytic leukemia (JMML)
is a rare hematopoietic malignancy of early
childhood, representing 2 to 3% of all pediat-
ric leukemia. Juvenile myelomonocytic leuke-
mia (JMML) usually runs an aggressive clini-
cal course, with median duration of survival
for children left untreated being less than 12
months from diagnosis.1
JMML share both myelodysplastic and my-
eloproliferative features.2 Two groups of MDS
are found in children. JMML has a unique clini-
cal presentation in children and infants. Adult
type is MDS. Patients less than one year of age
at diagnosis have a significantly better survival
than older children. Low platelets,elevated HbF
and complex cytogenic abnormalities i.e. mono-
somy 7 are unfavorable prognostic indicators.3
The pathogenesis of JMML arises from
dysregulation of signal transduction through
the RAS pathway. Potential causative muta-
tions or other genetic abnormalities in three
genes (e.g. RAS, neurofibromatosis type 1 and
PTPN11), all of which are positioned in the
Granulocyte-monocytes, colony stimulation
factor (GM CSF) RAS signal transduction path-
way, accounts for up to 75% of cases of JMML.4
CASE REPORT
An eight month old male child was admit-
ted with complaints of fever, cough and pallor
since last 6 months. He was well up to the age
of two months when he developed fever and
cough. He was treated by different medications
but symptoms used to subside temporarily and
than recur, with gradually increasing pallor.
The natal and postnatal history was unevent-
ful. There was no history of maternal fever,
rash, lymphadenopathy or past history of pre-
mature birth/abortion considering torch infec-
tion. There was no history of convulsions and
regression of milestone. He had two admissions
in hospital due to pneumonia.
On examination general condition was
stable with temperature of 99 F, pulse 99/min-
utes, R/R 29/minute, moderately anemic, one
café-au-lait spot about 5mm in size on the
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anterior chest wall. There was no cyanosis,
jaundice, lymphadenopathy, no petechael rash
and no other skin rash was detected. His
weight was 6.8 Kg, length was 67cm and FOC
was 43cm.
Spleen was palpable 8cm along its long axis
below left sub costal margin; it was firm in con-
sistency with well defined border. Liver was
3.5cm palpable below the right costal margin,
firm in consistency with sharp borders and
smooth surface, total span of liver was 7cm in
the mid clavicular line. Rest of the systemic
examination was unremarkable.
The investigations showed Hb 6gm/dl, TLC
29,400/cumm, (Neutrophil 58%, Lymphocytes
22%, Eosinophils 2%, Monocytes 10%, Myelo-
cytes 2% and Metamyelocytes 6%). Peripheral
smear showed anisocytosis, poikilocytosis,
rouloux formation, leucocytes shift to left.
Reticulocytes 6%. Electrophoresis revealed HbF
6%. Blood culture showed no growth. Chest
X-ray was normal, Ultrasound abdomen
showed hepatospleenomegally. Bone marrow
D/R showed myelopoiesis with hyperplasic
and moderately active dysplasia. Most myeloid
precursors show a granular cytoplasm. Blast
5%, M:E ratio was 10:1, lymphocytes and
plasma cells were normal. Increase in mono-
cytes and its precursors were noted.
DISCUSSION
In 1976, the French-American-British (FAB)
Cooperative Group initially defined refractory
anemia with excess blasts (RAEB) and CMML
as preleukemic states. Six years later, the FAB
group added three more categories to this clas-
sification scheme and adopted the present term
“myelodysplastic syndromes (MDS).5
The characteristic features, include
spleenomegaly, leukocytosis with monocytosis,
frequent skin involvement, thrombocytopenia
and anemia. Many patients are asymptomatic,
with the diagnosis established upon routine
laboratory screening.6
Infection remains the principal cause of
death in patients with MDS. Although fungal,
viral and mycobacterial infections can occur,
they are rare in the absence of concurrent
administration of immunosuppressive
agents.7
We treat our patient with antibiotics for in-
fections, packed cell (filtered) and platelet
transfusions for symptomatic anemia and
thrombocytopenia. The use of pre storage leuko
reduced transfusion products is recommended.
Along with the management of the symptoms
and complications we planed to start the rec-
ommended treatment protocol but his fever did
not subside rather he developed meningitis and
intracranial bleed and expired on 11th day of
admission.
Cytogenetic analysis, in vitro bone marrow
progenitor cultures, trephine biopsies, flow
cytometry and immunohistochemical studies
may be helpful, only those cases where the
morphology of the white cells were difficult to
appreciate or differentiate as opposed to this
case in which history, clinical  finding and
smear of blood film was clear enough to make
the diagnosis.
International Prognostic Scoring System
(IPSS) is of mutation and/or loss of heterozy-
gosity of the tumor suppresses gene p53. Such
alterations in the p53 configuration have been
commonly noted in MDS.8
Growth factors such as recombinant human
granulocyte colony-stimulating factor (G-CSF),
recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF), and
recombinant human erythropoietin (EPO) may
be used in MDS.9 The response of patients with
MDS to treatment with GM-CSF has been
disappointing.
On May 2, 2006, the United States FDA
approved decitabine (Dacogen®, MGI Pharma,
Inc.) for the treatment of patients with previ-
ously treated, untreated, de novo, and second-
ary MDS of all FAB subtypes and intermedi-
ate-1, intermediate-2, and high-risk IPSS
groups.
There is increasing use of matched unrelated
donor (MUD) transplants, which may be as
effective as HLA-matched sibling transplants.
For these patients, use of umbilical cord blood
as the donor source is being investigated.10
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Recommendations: All available treatments in
MDS are experimental, other than hematopoi-
etic cell transplantation (HCT). Prompt treat-
ment of infection, bleeding and anemia is nec-
essary for all patients, and may include use of
antibiotics and transfusions.
Future Directions: For interested patients,
relatives, and physicians, the Aplastic Anemia
and MDS International Foundation maintains
a website containing list of clinical trials.
http://www.aamds.org/
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Correspondence
Audit of pediatric prescriptions for
common paediatric problems
This is with reference to the above-cited ar-
ticle published in the Oct-Dec 2007 Part-II of Pa-
kistan Journal of Medical Sciences.1 The study
concluded that medicines are misused by the
pediatricians with both lower and higher quali-
fications. The authors have pleaded for active
measures to rationalize the prescribing habits of
the pediatricians. In this regards, I would like to
say that there have been numerous publications
highlighting the enormous problem of ‘irratio-
nal use of medicines’ in all the disciplines of medi-
cal science.2
Basically there is a huge “therapeutic deficit”
in the medical education and training of both un-
dergraduates and postgraduates. There is also
no programme of continued medical education
for the practicing doctors. This is due to the fact
that medical institutions in Pakistan do not have
departments of clinical therapeutics while in for-
eign countries every teaching hospital has a pro-
fessional unit of clinical therapeutics and clinical
pharmacology where education and training is
imparted to the undergraduate and post-gradu-
ate students, drug formularies for hospitals and
treatment guide-lines are made, medical audit
of treatments, research and continued education
of doctors is carried out. There, even the gen-
eral hospitals have specialists of this discipline.
It is important to understand that clinical thera-
peutics and clinical pharmacology is also a major
specialty, just like cardiology, pulmonology, gas-
troenterology, pediatrics etc. with an indispens-
able role in the discipline of the art and science
of medicines. Thus, establishment of such depart-
ments is the only way to tackle the problem of
misuse of drugs. Drugs are increasing in num-
bers explosively and nothing short of what is
stated above will work. The WHO Expert Com-
mittee has also advocated the dire necessity of
such departments.
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